Personalized Primary Care Membership Service HiTouch Health Launches Website, Open for Business
HiTouch Health offers a new business model for fee-based primary careSan Francisco, CA (PRWEB) May 18, 2012 HiTouch Health, a new membership-based medical service that provides highly personalized primary care services to patients in partnership with their personal physician, today announced the launch of its website – hitouchhealth.com.HiTouch Health brings a unique customer experience and an …
Read the Rest...Bionest Publishes Landmark Article on Quantitative Financial Analysis of Personalized Medicine Strategies
NEW YORK & PARIS–(BUSINESS WIRE)– Bionest Partners, a premier strategy and management consulting firm for the life science industries, and a recognized leader in personalized medicine (PM) strategy consulting, announces the publication of an article in a recent issue of Nature Reviews Drug Discovery (NRDD). This article, a result of the FDA Personalized Medicine Initiative a consortium effort across the FDA, industry and academia analyzes the key value drivers of PM development and commercialization strategies, elucidates a comprehensive approach for evaluating these strategies, and employs various modeling tools to support decision-making
Read the Rest...Cynvenio Biosystems Co-Founder & Chairman Honored by the Scholarship Foundation of Santa Barbara
WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)– Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research in circulating tumor cells, personalized medicine and the molecular diagnostics of cancer, announced today that Fred Gluck, its co-Founder and Chairman of the Board, will be the recipient of the 2012 South Coast Pioneer Award. The Scholarship Foundation of Santa Barbara will honor Fred Gluck and four other outstanding companies and individuals at the South Coast Business & Technology Awards dinner on June 14, 2012 at Fess Parkers Doubletree Resort in Santa Barbara, California.
Read the Rest...Ultrasensitive biosensor promising for medical diagnostics
This graphic depicts a new ultrasensitive biosensor that could open up new opportunities for early detection of cancer and “personalized medicine” tailored to the specific biochemistry of individual patients. The device, called a Flexure-FET biosensor, could be several hundred times more sensitive than other biosensors
Read the Rest...All Personal
The drug pipelines of pharmaceutical companies like AstraZeneca are full of therapeutics being developed for personalized medicine, writes Frank Vinluan at MedCity News. AstraZeneca’s Steve Labkoff says that 65 percent of the company’s pipeline is personalized medicine
Read the Rest...Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine'
Newswise New Brunswick, N.J., May 15, 2012 With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over one-size-fits-all methods. The Cancer Institute of New Jersey (CINJ) has been on the cutting-edge of this movement and is now launching a more concrete effort that is poised to change the way that molecular and genetic information is being used to diagnose and treat cancer an initiative known as precision medicine also known to many as personalized medicine.
Read the Rest...First, personalized medicine; next, personalized health insurance
Big data’s surging tide of information on medicines, patients and outcomes is changing how pharmaceutical companies develop new drugs. Consider AstraZeneca (NYSE:AZN). The data on whether a drug will work in certain patients makes that drug more valuable, said AstraZeneca’s Dr.
Read the Rest...Lab21 Unveils New Molecular Analysis Services at Greenville Site
CAMBRIDGE, England–(BUSINESS WIRE)– Lab21, the global specialist in personalized medicine and clinical diagnostics, is pleased to announce that routine analysis of clinical samples has begun from Lab21 Inc.s new CLIA laboratory in Greenville, South Carolina. The first assays in the test menu include a new Human Papillomavirus (HPV) High Risk and HPV 16 and 18 Genotyping Service.
Read the Rest...